CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, has signed a contract for distribution of its Vergenix Flowable Gel product covering Belarus, Kazakhstan, Georgia, Azerbaijan, Armenia and Uzbekistan, it was reported on Monday.
The firm stated that it has received its first order for a fee running into hundreds of thousands of US dollars. According to the terms of the deal, CollPlant will deliver a part of the order immediately and the remainder over the next six months, with the contract covering a five-year period.
The product is based on the firm's rhCollagen technology aimed at treating acute and chronic hard-to-heal wounds including diabetic ulcers, pressure sores, surgical cuts and trauma wounds.
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies